Human Genome Sciences, Inc.


Nov 26, 08

NEW STORY
08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Piper Jaffray Conference

    
Nov 17, 08

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Lazard Capital Conference

    
Nov 07, 08

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Deutsche Bank Conference

    
Nov 06, 08

16:05 ET Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments

    
Oct 30, 08

08:00 ET Human Genome Sciences to Sponsor Conference Call to Discuss Third Quarter 2008 Financial Results

    
Oct 03, 08

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Conference

    
08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Conference

    
Sep 18, 08

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at UBS Conference

    
Sep 08, 08

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Robert W. Baird Conference

    
Sep 04, 08

07:00 ET Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira

    
Sep 02, 08

16:05 ET Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma

    
08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Conference

    
Aug 27, 08

07:00 ET Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial

    
Aug 22, 08

07:00 ET Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer

    
Jul 30, 08

16:16 ET Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments

    
Jul 24, 08

07:00 ET Human Genome Sciences Appoints David P. Southwell to its Board of Directors

    
Jul 23, 08

16:05 ET Human Genome Sciences to Sponsor Conference Call to Discuss Second Quarter 2008 Financial Results

    
Jun 12, 08

07:00 ET Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus

    
Jun 09, 08

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Goldman Sachs Conference

    
May 30, 08

12:16 ET Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors

    
May 28, 08

07:00 ET Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives

    
May 21, 08

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentations at Analyst & Investor Meeting

    
May 16, 08

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Citi Conference

    
May 15, 08

07:00 ET Human Genome Sciences Names Kevin P. McRaith Vice President, Hepatology Franchise

    
May 08, 08

07:00 ET Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors

    
May 05, 08

16:01 ET Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments

    
Apr 28, 08

16:05 ET Human Genome Sciences to Sponsor Conference Call to Discuss First Quarter 2008 Financial Results

    
Apr 22, 08

07:09 ET Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials

    
Apr 16, 08

16:01 ET Human Genome Sciences to Sponsor Conference Call

    
16:00 ET Human Genome Sciences Advances Oncology Portfolio

    
Mar 14, 08

08:01 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Lehman Brothers Conference

    
08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Cowen Conference

    
Mar 03, 08

16:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Susquehanna Healthcare Conference

    
Feb 25, 08

16:00 ET Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress

    
Feb 21, 08

10:30 ET Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors

    
Feb 19, 08

16:00 ET Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2007 Financial Results

    
Feb 07, 08

07:00 ET Human Genome Sciences and Xencor Announce Antibody Collaboration

    
Feb 04, 08

16:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference

    
Jan 23, 08

07:01 ET Human Genome Sciences To Sponsor Conference Call

    
07:00 ET Human Genome Sciences Modifies Dosing in Achieve Trials of Albuferon(R)

    
Jan 07, 08

07:00 ET Human Genome Sciences Announces 2008 Goals and Reports Substantial Progress Toward Commercialization at JPMorgan Healthcare Conference

    
Jan 04, 08

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference

    
Dec 20, 07

07:02 ET Human Genome Sciences to Sponsor Conference Call

    
07:01 ET Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy

    
07:00 ET Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs

    
Dec 18, 07

07:00 ET New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies

    
Nov 26, 07

09:30 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Piper Jaffray Conference

    
Nov 12, 07

07:12 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Citi Biotech Conference

    
Nov 09, 07

16:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Sector Focus Conference

    
07:00 ET Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus

    
Nov 05, 07

07:02 ET Human Genome Sciences Announces Full Presentation of Quality-of-Life Results From Phase 2b Trial of Albuferon(R) for Hepatitis C

    
07:02 ET Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy

    
07:00 ET Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C

    
Nov 01, 07

07:01 ET Human Genome Sciences Announces Third Quarter 2007 Financial Results and Key Developments

    
07:00 ET Human Genome Sciences Completes Enrollment Ahead of Schedule in Second Phase 3 Albuferon(R) Trial

    
Oct 24, 07

16:00 ET Human Genome Sciences To Sponsor Conference Call To Discuss Third Quarter 2007 Financial Results

    
07:00 ET Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy

    
Sep 20, 07

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at UBS Investment Conference

    
Sep 14, 07

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference

    
Sep 07, 07

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference

    
Sep 04, 07

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference

    
Aug 31, 07

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference

    
Aug 28, 07

07:01 ET Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development

    
07:00 ET Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule

    
Aug 01, 07

07:00 ET Human Genome Sciences Announces Second Quarter 2007 Financial Results and Key Developments

    
Jul 25, 07

16:05 ET Human Genome Sciences to Sponsor Conference Call to Discuss Second Quarter 2007 Financial Results

    
Jun 14, 07

07:00 ET Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B(R) Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus

    
Jun 07, 07

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Goldman Sachs Conference

    
07:00 ET Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon(R)

    
Jun 04, 07

16:00 ET Human Genome Sciences Invites Investors To Listen To Webcast of Presentation at Bear Stearns Conference

    
May 30, 07

07:00 ET Human Genome Sciences and GlaxoSmithKline Initiate Second Phase 3 Clinical Trial of LymphoStat-B(R) in Systemic Lupus Erythematosus

    
May 24, 07

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bank of America Conference

    
May 18, 07

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Citigroup Conference

    
May 17, 07

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Conference

    
May 11, 07

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bank of America Conference

    
May 09, 07

07:00 ET Human Genome Sciences Announces First Quarter 2007 Financial Results and Key Developments

    
May 03, 07

08:30 ET Human Genome Sciences to Sponsor Conference Call to Discuss First Quarter 2007 Financial Results

    
May 01, 07

16:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Deutsche Bank Conference

    
Apr 27, 07

11:53 ET Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers

    
Apr 14, 07

10:00 ET Human Genome Sciences Reports Positive Interim Results of Phase 2b Trial of Albuferon(R)

    
Mar 16, 07

08:00 ET MedImmune Leases Human Genome Sciences Facility to Expand Cell Culture Influenza Vaccine Manufacturing Capabilities

    
Mar 15, 07

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Lehman Brothers Conference

    
Mar 09, 07

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Citigroup Conference

    
Feb 27, 07

16:08 ET Human Genome Sciences Announces Financial Results for 2006 and Progress Toward Commercialization

    
16:06 ET Human Genome Sciences Initiates Phase 3 Clinical Trial of Albuferon(R) With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C Genotypes 2 and 3

    
16:05 ET Human Genome Sciences Announces Positive Interim Results of Phase 2b Trial of Albuferon(R) With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C

    
Feb 21, 07

16:10 ET Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2006 Financial Results

    
Feb 13, 07

07:12 ET Human Genome Sciences and GlaxoSmithKline Announce Initiation of Phase 3 Clinical Trial of LymphoStat-B(R) in Systemic Lupus Erythematosus

    
Feb 02, 07

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference

    
Jan 26, 07

16:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Wachovia Conference

    
Jan 08, 07

16:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference

    
07:00 ET Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2007 Goals at JPMorgan Healthcare Conference

    
Dec 19, 06

07:00 ET Human Genome Sciences Initiates Phase 3 Clinical Trial of Albuferon(R) in Combination With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C

    
Nov 27, 06

16:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Piper Jaffray Conference

    
Nov 14, 06

16:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Conference

    
07:00 ET Human Genome Sciences Announces Positive 76-Week Results of Phase 2 Clinical Trial of LymphoStat-B(TM) in Systemic Lupus Erythematosus

    
Nov 08, 06

06:45 ET Human Genome Sciences Announces Financial Results for the Third Quarter of 2006

    
06:35 ET Human Genome Sciences Reports Interim Results of Phase 1b Clinical Trial of HGS-ETR1 With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors

    
Nov 01, 06

08:00 ET Human Genome Sciences to Sponsor Conference Call to Discuss Third Quarter 2006 Financial Results

    
Oct 31, 06

08:00 ET Human Genome Sciences Reports Positive Interim Results of Phase 2 Trials of Albuferon(TM) With Ribavirin in Patients With Chronic Hepatitis C

    
Oct 26, 06

07:00 ET Human Genome Sciences Announces Positive Special Protocol Assessment From FDA for Phase 3 Clinical Trials of LymphoStat-B(TM) In Systemic Lupus Erythematosus

    
Oct 19, 06

07:00 ET Human Genome Sciences Appoints Kevin Starr to Its Board of Directors

    
Oct 16, 06

07:00 ET Human Genome Sciences Reports Positive Interim Quality-of-Life Data From Phase 2B Trial of Albuferon(TM) with Ribavirin in Treatment-Naive Hepatitis C Patients

    
Oct 04, 06

07:01 ET Human Genome Sciences Reports Significant Progress and Outlines Its Next Steps on the Path to Commercialization

    
07:00 ET Human Genome Sciences Announces Phase 3 Clinical Development Program for Albuferon(TM) in Chronic Hepatitis C

    
Sep 29, 06

17:00 ET Human Genome Sciences Reports Positive Results of Phase 1 Clinical Trial of CCR5 mAb in Patients Infected with HIV-1

    
Sep 27, 06

16:10 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentations at Analyst & Investor Meeting

    
Sep 21, 06

08:30 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at UBS Securities Conference

    
Sep 07, 06

16:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference

    
Aug 30, 06

16:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference

    
Aug 29, 06

16:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Investment Conference

    
Aug 09, 06

06:31 ET Human Genome Sciences Announces Financial Results for the Second Quarter of 2006

    
06:30 ET Human Genome Sciences Announces Phase 3 Clinical Development Program for LymphoStat-B(TM) in Systemic Lupus Erythematosus

    
Aug 03, 06

07:00 ET Human Genome Sciences to Sponsor Conference Call to Discuss Second Quarter 2006 Financial Results

    
Jul 20, 06

07:00 ET Human Genome Sciences Initiates Randomized Phase 2 Clinical Trial of HGS-ETR1 in Combination With Bortezomib

    
Jul 10, 06

10:18 ET Human Genome Sciences Names Timothy C. Barabe Senior Vice President and Chief Financial Officer

    
Jun 22, 06

07:00 ET Human Genome Sciences Announces Full Presentation of Results of Phase 2 Clinical Trial of LymphoStat-B(TM) in Systemic Lupus Erythematosus

    
Jun 20, 06

08:31 ET Human Genome Sciences to Sponsor Conference Call to Discuss U.S. Government Agreement to Purchase ABthrax(TM) for the Strategic National Stockpile

    
08:30 ET U.S. Government Agrees to Purchase ABthrax(TM) From Human Genome Sciences for the Strategic National Stockpile

    
Jun 12, 06

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Pacific Growth Conference

    
07:01 ET Human Genome Sciences Completes Transaction Establishing CoGenesys as an Independent Company

    
07:00 ET CoGenesys Raises $55 Million in Series A Financing

 
Jun 09, 06

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Goldman Sachs Conference

    
Jun 06, 06

01:16 ET Human Genome Sciences to Sponsor Conference Call to Discuss Collaboration With Novartis for Development and Commercialization of Albuferon(TM)

    
01:15 ET Human Genome Sciences Announces Collaboration with Novartis for Development and Commercialization of Albuferon(TM)

    
Jun 02, 06

13:40 ET Human Genome Sciences Names Margery B. Fischbein Vice President, Business Development & Strategic Planning

    
May 12, 06

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bank of America Conference

    
May 10, 06

07:00 ET Human Genome Sciences Announces Results for First Quarter of 2006

    
May 05, 06

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Robert W. Baird Conference

    
May 02, 06

17:00 ET Human Genome Sciences Facilities Transactions to Generate $380 Million in Additional Cash Available for Operations

    
May 01, 06

07:02 ET Human Genome Sciences Presents Interim Results of Phase 2 Trial of Albuferon(TM) with Ribavirin in Patients with Chronic Hepatitis C Who Failed to Respond to Previous Therapy

    
07:00 ET Human Genome Sciences Presents Interim Results of Phase 2b Trial of Albuferon(TM) With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C

    
Mar 14, 06

08:06 ET Human Genome Sciences Reports Positive Interim Results of Phase 2 Trial of Albuferon(TM) In Combination With Ribavirin In Treatment-Experienced Patients With Chronic Hepatitis C

    
08:05 ET Human Genome Sciences to Sponsor Conference Call to Discuss Interim Results of Two Phase 2 Trials of Albuferon(TM)

    
08:02 ET Human Genome Sciences Announces Positive Interim Results of Phase 2b Clinical Trial Of Albuferon(TM) in Combination With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C

    
Mar 10, 06

08:31 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Citigroup Conference

    
Mar 06, 06

08:01 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Conference

    
Mar 03, 06

08:01 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Lehman Brothers Conference

    
Feb 22, 06

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Citigroup Conference

    
Feb 10, 06

08:01 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bio Investor Conference

    
Feb 09, 06

09:38 ET Human Genome Sciences Reports Financial Results for Full Year and Fourth Quarter 2005

    
Feb 03, 06

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference

    
Jan 10, 06

07:10 ET Human Genome Sciences Reports on Progress Toward Commercialization and Announces 2006 Goals at JPMorgan Healthcare Conference

    
07:01 ET Human Genome Sciences Licenses Worldwide Intellectual Property Rights for Target Antigen to PDL BioPharma

    
07:01 ET Human Genome Sciences Receives Milestone Payment From GlaxoSmithKline for Filing of GSK716155 IND Application to Begin Phase 1 Trials in the Treatment of Diabetes

    
Jan 09, 06

17:02 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference

    
07:01 ET Human Genome Sciences Announces License Agreement With Amgen

    
Jan 06, 06

16:01 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference

    
Dec 13, 05

16:06 ET Human Genome Sciences to Sponsor Conference Call to Discuss Decision to Spin Off CoGenesys Division as an Independent Company

    
16:05 ET Human Genome Sciences Announces Decision to Spin Off CoGenesys Division as an Independent Company

    
Dec 12, 05

13:33 ET Human Genome Sciences Reports Results of Phase 2 Clinical Trial of HGS-ETR1 In Patients With Advanced Non-Hodgkin's Lymphoma

    
Dec 01, 05

08:30 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at First Albany Conference

    
07:00 ET Human Genome Sciences Appoints Tuan Ha-Ngoc to its Board of Directors

    
Nov 17, 05

12:31 ET Human Genome Sciences Reports Results of Phase 1 Clinical Trials of HGS-ETR2 in Patients with Advanced Solid Tumors

    
12:30 ET Human Genome Sciences Reports Interim Results of Phase 1b Clinical Trials of HGS-ETR1 in Combination With Chemotherapy in Patients With Advanced Solid Tumors

    
07:02 ET Human Genome Sciences Reports Phase 2 Results for LymphoStat-B(TM) (Belimumab) In Patients With Rheumatoid Arthritis

    
Nov 15, 05

12:01 ET Human Genome Sciences Reports Interim Results of Phase 2 Clinical Trial of Albuferon(TM) in Combination With Ribavirin in Treatment-Experienced Hepatitis C Patients

    
08:01 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Credit Suisse First Boston Conference

    
Nov 08, 05

16:07 ET Human Genome Sciences Calls for Redemption All of Its Remaining Outstanding Subordinated Notes Due 2007

    
Nov 03, 05

08:01 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at CIBC World Markets Conference

    
Nov 01, 05

07:10 ET Human Genome Sciences Reports Results of Phase 2 Clinical Trial of HGS-ETR1 In Patients With Advanced Colorectal Cancer

    
Oct 25, 05

07:03 ET Human Genome Sciences Announces Financial Results for the Third Quarter of 2005

    
06:55 ET Human Genome Sciences Completes Patient Enrollment in a Phase 2b Clinical Trial of Albuferon(TM) in Combination With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C

    
Oct 12, 05

07:00 ET Human Genome Sciences Appoints Robert C. Young, M.D., to Its Board of Directors

    
Oct 05, 05

07:02 ET Human Genome Sciences to Sponsor Conference Call to Discuss Phase 2 Clinical Results of LymphoStat-B(TM) in Systemic Lupus Erythematous Patients

    
07:01 ET Human Genome Sciences Reports Results of a Phase 2 Clinical Trial of LymphoStat-B(TM) in Patients With Systemic Lupus Erythematosus

    
Oct 03, 05

07:01 ET Human Genome Sciences Awarded Two-Phase Contract to Supply ABthrax(TM) for the Treatment of Inhalational Anthrax Disease to the U.S. Government

    
Sep 22, 05

17:05 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at UBS Conference

    
Sep 15, 05

08:15 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Banc of America Conference

    
Sep 08, 05

08:15 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference

    
Sep 06, 05

08:15 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury Conference

    
Sep 02, 05

08:15 ET Human Genome Sciences Invites Investors to Listen to Webcast of Discussion at Thomas Weisel Partners Conference

    
Aug 18, 05

07:00 ET GlaxoSmithKline Exercises Option to Human Genome Sciences' Trail Receptor Antibody

    
Aug 09, 05

12:37 ET Human Genome Sciences Announces Completion of Offering

    
Aug 04, 05

11:21 ET Human Genome Sciences Announces Pricing of $230 Million Private Placement of Convertible Subordinated Notes

    
Aug 03, 05

16:06 ET Human Genome Sciences Announces Proposed Private Offering of Convertible Subordinated Notes

    
Aug 01, 05

07:04 ET Human Genome Sciences Receives Milestone Payments from GlaxoSmithKline for GSK716155 Progress

    
Jul 25, 05

16:15 ET Human Genome Sciences Announces Financial Results for the Second Quarter of 2005

    
Jul 22, 05

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Banc of America Conference

    
Jul 18, 05

16:03 ET Human Genome Sciences Publishes Results of Phase 1 Clinical Trial of ABthrax(TM) for Use in Prevention and Treatment of Anthrax Infection

    
Jul 14, 05

07:04 ET Human Genome Sciences Names Barry A. Labinger Executive Vice President and Chief Commercial Officer

    
Jul 07, 05

07:00 ET GlaxoSmithKline Exercises Option to LymphoStat-B(TM)

    
Jul 05, 05

07:21 ET Human Genome Sciences Reports Results of Phase 2 Clinical Trial of HGS-ETR1 In Patients With Non-Small Cell Lung Cancer

    
Jun 13, 05

07:15 ET Human Genome Sciences Reports Interim Results of Phase 2 Clinical Trial of HGS-ETR1 in Patients with Advanced Non-Hodgkin's Lymphoma

    
Jun 10, 05

08:01 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Goldman Sachs Conference

    
Jun 01, 05

07:17 ET Human Genome Sciences Initiates Phase 2b Clinical Trial of Albuferon(TM) in Combination With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C

    
May 26, 05

07:54 ET Human Genome Sciences Reports on Progress Toward Commercialization

    
May 19, 05

08:30 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Analyst & Investor Meeting

    
May 17, 05

07:17 ET Human Genome Sciences Reports Results of Preclinical Study Comparing Anti-Viral Activity of Albuferon(TM) And Three Other Forms of Interferon Alpha Used to Treat Hepatitis C

    
07:15 ET Human Genome Sciences Reports Results Of Phase 1 Clinical Trials of HGS-ETR2 and HGS-ETR1 In Patients With Advanced Solid Tumors

    
May 12, 05

16:10 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Banc of America Conference

    
May 09, 05

17:14 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Robert W. Baird Growth Stock Conference

    
Apr 25, 05

16:18 ET Human Genome Sciences Announces Financial Results for First Quarter of 2005

    
Apr 18, 05

07:08 ET Human Genome Sciences Reports Results of Phase 1 Clinical Trial of HGS-ETR1 in Patients With Advanced Solid Tumors

    
Apr 14, 05

10:45 ET Human Genome Sciences Reports Positive Results of Phase 2 Clinical Trial of Albuferon(TM) in Treatment-Naive Patients With Chronic Hepatitis C

    
Apr 06, 05

06:30 ET Human Genome Sciences Reports Results of a Phase 2 Clinical Trial of LymphoStat-B(TM) in Patients with Rheumatoid Arthritis

    
Mar 30, 05

07:15 ET Human Genome Sciences Begins Dosing of Patients in a Phase 1 Clinical Trial of CCR5 mAb in Patients Infected With HIV-1

    
Mar 28, 05

16:10 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Lehman Brothers' Conference

    
Mar 11, 05

16:15 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at SG Cowen Conference

    
Mar 03, 05

07:15 ET Human Genome Sciences Completes Patient Enrollment in a Phase 2 Clinical Trial of HGS-ETR1 for the Treatment of Non-Hodgkin's Lymphoma

    
Feb 25, 05

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcasts From Two Securities Conferences

    
Feb 23, 05

07:15 ET Human Genome Sciences Completes Patient Enrollment in a Phase 2 Clinical Trial of HGS-ETR1 for the Treatment of Colorectal Cancer

    
Feb 16, 05

07:15 ET Human Genome Sciences Completes Enrollment in a Phase 2 Clinical Trial of Albuferon(TM) in Treatment-Naive Patients with Chronic Hepatitis C

    
Feb 07, 05

16:15 ET Human Genome Sciences Reports Financial Results for Full Year and Fourth Quarter 2004

    
07:55 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference

    
Jan 20, 05

16:05 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Piper Jaffray Health Care Conference

    
Jan 10, 05

07:08 ET Human Genome Sciences Reports On Progress Of Clinical Trials And Announces Goals for 2005 at JPMorgan Healthcare Conference

    
07:01 ET Human Genome Sciences Receives FDA Clearance to Initiate Clinical Development of a New Compound for the Treatment of HIV/AIDS

    
Jan 07, 05

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Healthcare Conference

    
Dec 22, 04

16:41 ET Human Genome Sciences Announces Agreement to Exit Facility at 9800 Medical Center Drive

    
Nov 30, 04

07:17 ET Human Genome Sciences Initiates Phase 2 Clinical Trial of Albuferon(TM) In Combination With Ribavirin in Treatment-Experienced Hepatitis C Patients

 
07:16 ET Human Genome Sciences Completes Patient Enrollment in A Phase 2 Clinical Trial of HGS-ETR1 for the Treatment of Non-Small Cell Lung Cancer

 
Nov 22, 04

07:15 ET H. Thomas Watkins Appointed Chief Executive Officer of Human Genome Sciences

 
Nov 08, 04

08:15 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at CIBC World Markets Investment Conference

 
Nov 02, 04

12:43 ET Human Genome Sciences Characterizes Panel of Novel Human Monoclonal Antibodies That Specifically Antagonize the CCR5 Receptor and Block HIV-1 Entry

 
12:42 ET Human Genome Sciences Reports Results of Preclinical Studies of HGS-TR2J (TRAIL-R2 mAb) and TRAIL-R2 Protein Expression

 
12:41 ET Human Genome Sciences Reports Positive Results of Phase 1/2 Clinical Trial of Albuferon(TM) in Chronic Hepatitis C

 
Oct 26, 04

07:17 ET Human Genome Sciences Announces Third Quarter 2004 Financial Results

 
07:15 ET Human Genome Sciences Announces Agreement With GlaxoSmithKline for Development and Commercialization of Novel Drug to Treat Diabetes

 
Oct 19, 04

12:48 ET Human Genome Sciences Announces Completion of Repurchase of Convertible Subordinated Notes

 
Oct 13, 04

08:03 ET Human Genome Sciences Begins Dosing of Patients in a Phase 2 Clinical Trial of HGS-ETR1 in Non-Hodgkin's Lymphoma

 
08:00 ET Human Genome Sciences Initiates a Phase 2 Clinical Trial of HGS-ETR1 in Patients With Colorectal Cancer

 
Oct 04, 04

12:21 ET Human Genome Sciences Announces Completion of Offering

 
Oct 01, 04

08:15 ET Human Genome Sciences Reports Results of Preclinical Studies of TRAIL-R1 and TRAIL-R2 Agonistic Human Monoclonal Antibodies at EORTC-NCI-AACR Symposium

 
Sep 29, 04

09:40 ET Human Genome Sciences Reports Results of Ongoing Phase 1 Clinical Trials of HGS-ETR1 in Patients With Advanced Cancers

 
08:31 ET Human Genome Sciences Reports Initial Results of Phase 1 Clinical Trials of HGS-ETR2 (TRAIL-R2 MAB) in Patients With Advanced Cancers

 
08:02 ET Human Genome Sciences Announces Pricing of $250 Million Private Placement of Convertible Subordinated Notes

 
Sep 27, 04

16:01 ET Human Genome Sciences Announces Proposed Private Offering of Convertible Subordinated Notes

 
11:03 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at UBS Conference

 
08:15 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at UBS Conference

    
Sep 20, 04

08:15 ET Argeris (Jerry) N. Karabelas, Ph.D., to Become Chairman of Human Genome Sciences Board; Craig A. Rosen, Ph.D., Named President and Chief Operating Officer

    
Sep 15, 04

08:15 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Banc of America Conference

    
Sep 08, 04

08:15 ET Human Genome Sciences Advances Anti-Cancer Drug to Phase 2 Clinical Development

    
Sep 07, 04

16:10 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury/Thomson Financial Conference

    
Aug 24, 04

08:15 ET Human Genome Sciences Initiates Clinical Development of New Drug for the Treatment of Cancer

    
Jul 30, 04

07:45 ET Human Genome Sciences Reports Second Quarter 2004 Financial Results

    
Jul 29, 04

08:20 ET Human Genome Sciences Completes Patient Enrollment in a Phase 2 Clinical Trial of LymphoStat-B(Tm) for the Treatment of Rheumatoid Arthritis

    
08:15 ET Human Genome Sciences Completes Patient Enrollment in a Phase 2 Clinical Trial of LymphoStat-B(TM) for the Treatment of Systemic Lupus Erythematosus

    
03:20 ET Human Genome Sciences Completes Patient Enrollment in a Phase 2 Clinical Trial of LymphoStat-B(TM) for the Treatment of Rheumatoid Arthritis

    
03:15 ET Human Genome Sciences Completes Patient Enrollment in a Phase 2 Clinical Trial of LymphoStat-B(TM) for the Treatment of Systemic Lupus Erythematosus

    
Jul 27, 04

16:05 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Banc of America Conference

    
Jun 07, 04

09:05 ET Human Genome Sciences Reports Results of Phase 1 Clinical Trials of HGS-ETR1 (TRAIL-R1 MAB) in Patients with Advanced Cancers

    
Jun 03, 04

16:15 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Goldman Sachs Conference

    
May 26, 04

08:20 ET Human Genome Sciences Initiates Phase 2 Clinical Trial of Albuferon(TM) for the Treatment of Chronic Hepatitis C

    
Apr 30, 04

08:15 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Robert W. Baird Conference

    
Apr 28, 04

16:11 ET Human Genome Sciences Reports Financial Results for First Quarter of 2004

    
Apr 23, 04

08:20 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at CIBC World Markets Conference

    
Mar 31, 04

08:06 ET Human Genome Sciences Announces License Agreement With DakoCytomation for Development of Pharmacogenomic Diagnostic Assays

    
Mar 30, 04

08:05 ET Human Genome Sciences Receives Milestone Payment From GlaxoSmithKline for Initiation of Clinical Trials of Genomics-Derived Drug for Cardiovascular Disease

    
Mar 25, 04

08:05 ET Human Genome Sciences to Sharpen Focus - Announces Plans to Concentrate on Drugs of Highest Potential

    
08:05 ET William Haseltine Plans to Retire as Chairman and Chief Executive Officer of Human Genome Sciences

    
Mar 09, 04

08:01 ET Human Genome Sciences Reports Results of Phase 1 Clinical Trial of ABthrax(TM) for Use in Prevention and Treatment of Anthrax Infection

    
Mar 05, 04

08:20 ET Human Genome Sciences Invites Investors to Listen to Webcast Of Presentations at SG Cowen Conference

    
08:15 ET Human Genome Sciences Invites Investors to Listen to Webcast Of Presentation at JMP Securities Conference

    
Mar 04, 04

08:33 ET Human Genome Sciences Announces Selection of Lymphostat-B(TM) for Participation in FDA's Continuous Marketing Application Pilot 2 Program

    
Mar 03, 04

08:15 ET Human Genome Sciences Appoints New Members to Its Board of Directors

    
Feb 27, 04

08:15 ET Human Genome Sciences Invites Investors to Listen to Webcast Of Presentation at Lehman Brothers Conference

    
Feb 20, 04

08:18 ET Human Genome Sciences to Participate in BIO CEO + Investor 2004 Conference

    
Feb 17, 04

17:10 ET Human Genome Sciences Confirms Stock Sale and Transfer By Chairman and CEO

    
08:15 ET Human Genome Sciences Awarded 'Workplace Excellence' Seal of Approval By Maryland Work-Life Alliance

    
Feb 10, 04

08:15 ET Human Genome Sciences Reports Financial Results For Full Year and Fourth Quarter 2003

    
Feb 05, 04

16:05 ET Human Genome Sciences to Sponsor Conference Call to Discuss Full Year and Fourth Quarter 2003 Financial Results

    
Feb 02, 04

17:00 ET Human Genome Sciences Reports Results of Phase 2 Clinical Trial of Repifermin in Patients With Cancer Therapy-Induced Mucositis

    
Jan 23, 04

08:15 ET Human Genome Sciences Invites Investors to Listen to Webcast Of Presentation at Piper Jaffray Conference

    
Jan 12, 04

07:45 ET Human Genome Sciences Updates Progress of Six Drugs in Clinical Trials at JPMorgan Conference

    
Jan 09, 04

08:15 ET Human Genome Sciences Invites Investors to Listen to Webcast Of Presentation at JPMorgan Conference

    
Jan 08, 04

07:45 ET Human Genome Sciences Initiates Phase 2 Clinical Trial Of LymphoStat-B(TM) for the Treatment Of Rheumatoid Arthritis

    
Dec 18, 03

13:32 ET Human Genome Sciences Announces License Agreement With Pfizer

    
Dec 09, 03

12:30 ET Human Genome Sciences Reports Interim Results of Phase 1 Clinical Trials of LymphoRad(TM)(131) at 45th Annual Meeting of the American Society of Hematology

    
Dec 08, 03

16:15 ET Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Harris Nesbitt Gerard Conference

    
Dec 05, 03

08:59 ET Genomics-Derived Drug for Cardiovascular Disease to Advance To Phase 3 Clinical Trials

    
Nov 10, 03

08:00 ET Human Genome Sciences Invites Investors to Listen to Webcast Of Presentation at Credit Suisse First Boston Conference

    
Nov 06, 03

08:01 ET Human Genome Sciences Invites Investors to Listen to Webcast Of Presentation at CIBC World Markets Conference

    
Oct 28, 03

08:25 ET Human Genome Sciences Reports Results of Phase 1 Clinical Trial of Lymphostat-B(TM) in Patients with Systemic Lupus Erythematosus

    
08:18 ET Human Genome Sciences Reports Third Quarter 2003 Financial Results

    
08:05 ET Human Genome Sciences Reports Interim Results of Phase 1/2 Clinical Trial of Albuferon(TM) in Patients Infected With Hepatitis C Virus

    
Oct 23, 03

16:47 ET Human Genome Sciences to Host Conference Call to Discuss Third Quarter 2003 Financial Results

    
16:05 ET Human Genome Sciences to Host Conference Call to Discuss Second Quarter 2003 Financial Results

    
Sep 25, 03

16:42 ET Human Genome Sciences Initiates Phase 2 Clinical Trial of LymphoStat-B(TM) for the Treatment of Systemic Lupus Erythematosus

    
16:42 ET Human Genome Sciences Reports Results of Clinical Trial of Repifermin in Patients with Chronic Venous Ulcers

    
Sep 18, 03

16:15 ET Human Genome Sciences Invites Investors to Listen To Webcast of Presentation at UBS Warburg Conference

    
Sep 17, 03

16:47 ET Human Genome Sciences Appoints New Members to its Board of Directors

    
Sep 15, 03

07:45 ET Human Genome Sciences Describes Activity of ABthrax(TM) at 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

    
Sep 04, 03

10:58 ET Human Genome Sciences Names Perry Karsen Senior Vice President, Business Development

    
08:20 ET Human Genome Sciences Invites Investors to Listen to Webcast Of Presentation at Bear Stearns Conference

    
Sep 02, 03

08:20 ET Human Genome Sciences Invites Investors to Listen To Webcast of Presentation at BioCentury And Thomson Financial/Carson Conference

    
Aug 19, 03

08:31 ET Human Genome Sciences Receives Fast Track Product Designation For ABthrax for Prevention and Treatment of Anthrax Infections

    
Aug 07, 03

08:15 ET Human Genome Sciences Announces License Agreement With Genentech

    
Jul 29, 03

08:15 ET Human Genome Sciences Reports Second Quarter 2003 Financial Results

    
Jul 11, 03

08:30 ET Human Genome Sciences Initiates Clinical Development of Trail Receptor-2 Antibody for Treatment of Cancer